1. Home
  2. REVB vs XPON Comparison

REVB vs XPON Comparison

Compare REVB & XPON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REVB
  • XPON
  • Stock Information
  • Founded
  • REVB 2020
  • XPON 2016
  • Country
  • REVB United States
  • XPON United States
  • Employees
  • REVB N/A
  • XPON N/A
  • Industry
  • REVB Biotechnology: Pharmaceutical Preparations
  • XPON Electronic Components
  • Sector
  • REVB Health Care
  • XPON Technology
  • Exchange
  • REVB Nasdaq
  • XPON Nasdaq
  • Market Cap
  • REVB 2.8M
  • XPON 2.7M
  • IPO Year
  • REVB N/A
  • XPON 2022
  • Fundamental
  • Price
  • REVB $2.92
  • XPON $0.95
  • Analyst Decision
  • REVB
  • XPON
  • Analyst Count
  • REVB 0
  • XPON 0
  • Target Price
  • REVB N/A
  • XPON N/A
  • AVG Volume (30 Days)
  • REVB 147.3K
  • XPON 45.4K
  • Earning Date
  • REVB 05-09-2025
  • XPON 05-13-2025
  • Dividend Yield
  • REVB N/A
  • XPON N/A
  • EPS Growth
  • REVB N/A
  • XPON N/A
  • EPS
  • REVB N/A
  • XPON N/A
  • Revenue
  • REVB N/A
  • XPON $5,624,939.00
  • Revenue This Year
  • REVB N/A
  • XPON $61.26
  • Revenue Next Year
  • REVB N/A
  • XPON N/A
  • P/E Ratio
  • REVB N/A
  • XPON N/A
  • Revenue Growth
  • REVB N/A
  • XPON N/A
  • 52 Week Low
  • REVB $2.36
  • XPON $0.67
  • 52 Week High
  • REVB $60.80
  • XPON $236.00
  • Technical
  • Relative Strength Index (RSI)
  • REVB 45.77
  • XPON 53.14
  • Support Level
  • REVB $2.76
  • XPON $0.74
  • Resistance Level
  • REVB $3.62
  • XPON $0.91
  • Average True Range (ATR)
  • REVB 0.41
  • XPON 0.08
  • MACD
  • REVB 0.02
  • XPON 0.03
  • Stochastic Oscillator
  • REVB 34.12
  • XPON 86.25

About REVB Revelation Biosciences Inc.

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

About XPON Expion360 Inc.

Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.

Share on Social Networks: